



I hereby certify that this correspondence is being deposited with the
United States Postal Service with sufficient postage as first class
in an envelope addressed to: Commissioner for Patents
P.O. Box 1450, Alexandria, VA 22313-1450 on:

14 February 2005
Date of Deposit

Our File No. LOU02-016-US

Paul E. Rauch, Ph.D.

Name

Signature

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)	
)	
Cedric Francois)	
)	
Serial No. 10/724,527)	Examiner Gyan Chandra
)	
Filing Date: November 28, 2003)	Group Art Unit No. 1646
)	
For COMPOSITIONS AND METHODS)	
FOR TREATING TRANSPLANTS)	

RESTRICTION RESPONSE

M.S. - Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In response to the Office Action of January 12, 2005, Applicant elects Group III, with traverse, claims 20-23. Furthermore, as a single disclosed species of phospholipids, applicant elects (i) DOPC, which is 1,2-dioleoyl-sn-glycero-3-phosphocholine; and as a single disclosed species of polar lipid, applicant elects (iii) formula XVIII. Claims 20-23 (as well as claims 24-30) read on the elected species, and all these claims are generic.

Applicant also requests that the examiner reconsider the grouping of the claims, and include claims 24-26, since they include all the limitations of claim 20, as well as claims 27-31, as they all depend from claim 20.